One-hundred-forty first-year students from the Icahn School of Medicine at Mount Sinai symbolically marked the start of their medical education by receiving white coats and stethoscopes, and reciting a student oath at the 16th annual White Coat Ceremony, held recently in Stern Auditorium.
The Boards of Trustees of The Mount Sinai Medical Center and Continuum Health Partners announced on Monday, September 30, the establishment of the Mount Sinai Health System. This new health system includes Icahn School of Medicine at Mount Sinai, seven major member hospital campuses in New York City, an extensive network of approximately 45 ambulatory care locations, 12 free-standing ambulatory surgery centers, and more than 40 clinical and academic relationships with local health care organizations—all throughout the greater metropolitan region.
The Icahn School of Medicine at Mount Sinai, one of the nation’s leading medical schools, along with its Graduate School of Biomedical Sciences, will serve to integrate all clinical and research missions for the seven member hospital campuses and vast network of ambulatory facilities in the new Mount Sinai Health System.
Today’s standard therapies for cancer exist because people have participated in clinical trials – yet choosing to participate in a cancer clinical trial is an important personal decision that can be intimidating for many patients. In order to better help patients understand cancer clinical trials, the reasons to participate in them, and clinical research at Mount Sinai, The Tisch Cancer Institute has released a new video, “Clinical Trials at Mount Sinai: Moving the Field Forward.”
Multiple Sclerosis is an inflammatory demyelinating disorder of the Central Nervous System of debated etiology. While there is general consensus regarding the role of an active immune system in myelin destruction, the questions related to the initial events triggering immune system involvement remain unanswered and the identity of disease course modifiers is only partially understood. Epidemiological studies have suggested the possibility that disease onset and course are the result of an interaction between genetic susceptibility and environmental factors, though much remains to be learned about the identity of the environmental factors and whether they can be modified. Among the proposed variables affecting MS are geographic location, smoking, vitamin D levels and the much debated diet and infections.
Mount Sinai’s Neuroscience Training Program offers predoctoral students an exciting and distinctive curriculum taught by a nationally and internationally recognized faculty, and a laboratory experience that builds on groundbreaking, cutting edge expertise in basic and translational neuroscience across a wide range of psychiatric and neurological disorders. A student’s training experience uniquely interfaces basic research within a clinical context by virtue of the close apposition of basic and clinical research and clinical treatment programs at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Hospital. Indeed, all graduate students take a class in clinical neuroscience where they meet patients with brain diseases.
Kravis Children’s Hospital at Mount Sinai is now ranked in 7 of the 10 specialties measured by U.S. News & World Report in its 2013-14 “Best Children’s Hospital” annual guidebook, moving up from six specialties last year. Significantly, Mount Sinai is also ranked as the No . 2 pediatric center in New York City, and is tied for No . 2 in the New York City metropolitan area out of the nine ranked children’s hospitals.
The seven specialties are: diabetes & endocrinology (No . 25), gastroenterology & GI surgery (No . 25),
nephrology (No . 26), urology (No . 28), pulmonology (No . 36), cancer (No . 46), and cardiology & heart surgery (No . 50). Read more
Two legendary mentors at Icahn School of Medicine at Mount Sinai, Arthur H. Aufses Jr., MD, and Nathan Kase, MD, were honored in May by Mount Sinai’s Institute for Medical Education (IME) with Annual Excellence in Teaching Awards that bear their names.
Dr. Aufses and Dr. Kase were cited by IME’s leaders for their legacy to medical education. Dr. Aufses, Professor of Surgery, and Health, Evidence and Policy, retired as Chairman of the Department of Surgery in 1996. Dr. Kase, Dean Emeritus, and Professor of Obstetrics, Gynecology and Reproductive Science, and Medicine, served as Dean of the Medical School from 1985 through 1998.
Mount Sinai’s leadership in biomedical research and patient care, together with Rensselaer Polytechnic Institute’s expertise in engineering and invention prototyping, form the foundation for a new academic affiliation agreement between the two institutions. The agreement signals a new era of biomedical discovery and entrepreneurship for the Icahn School of Medicine at Mount Sinai and Rensselaer.
The partnership, commemorated at a signing ceremony on Wednesday, May 22, promotes collaboration in educational programs and research, with the ultimate goal of developing innovative diagnostic tools and treatments for patients around the world.
Shutting down inflammation within the body, and then harnessing the immune system to recognize and destroy cancer cells, could provide the one-two punch needed to effectively treat head and neck cancers, according to researchers at Icahn School of Medicine at Mount Sinai.
Research into the pivotal role played by the inflammatory molecule inducible nitric oxide synthase (iNOS) in promoting cancer growth and immune evasion is being led by Andrew G. Sikora, MD, PhD, Assistant Professor and Director of Head and Neck Translational Research in the Department of Otolaryngology, Head and Neck Surgery.